Pattern of expression of c-erbB-2 oncoprotein in human fetuses. by Quirke, P. et al.
C The Macmillan Press Ltd., 1989
Pattern of expression of c-erbB-2 oncoprotein in human fetuses
P. Quirke1, A. Pickles1, N.L. Tuzi2, 0. Mohamdeel & W.J. Gullick2
'Department of Pathology, University of Leeds, Leeds LS2 9JT, UK, and 2Imperial Cancer Research Fund Oncology Unit,
Royal Postgraduate Medical School, Hammersmith Hospital, Ducane Road, London WJ2 OHS, UK.
S_ry 1The pattern of expression of the c-erbB-2 oncoprotein was investigatdd in whole mount
preparations of 11 human fetuses by immunocytochemistry using two polyclonal antibodies, 20N and 21N.
c-erbB-2 was widely expressed within all three germ layers. Expression remained relatively constant in
epitheliaL mesodermal and extraembryonic tissues, but varied over time during the development of the fetal
skeleton. Western blotting failed to detect c-erbB-2 in normal fetal tissues but did confirm expression in a
microvillous membrane preparation of placenta. c-erbB-2 expression is widespread in the human fetus and
occurs at an earlier stage than epidermal growth factor receptor.
The c-erbB-2 proto-oncogene encodes a 4.6 kb mRNA which
specifies a 190,000 molecular weight glycoprotein with tyro-
sine kinase activity. This 1,255 amino acid protein reveals
extensive sequence homology with the epidermal growth
factor receptor (EGF-R), but unlike EGF-R, no ligand has
yet been identified (for a review see Gullick & Venter, 1989).
Amplification of the c-erbB-2 proto-oncogene has been
demonstrated in a wide range of adenocarcinomas including
those of the breast (Slamon et al., 1987; Venter et al., 1987;
Van de Vijver et al., 1987, 1988), stomach (Yokota et al.,
1986, 1988), salivary gland (Semba et al., 1985), kidney
(Yokota et al., 1986) and lung (Cline & Battifora, 1987) and
appears to be related to prognosis in breast cancer (Slamon
et al., 1987; Zhou et al., 1987). The presence of amplification
in colonic adenocarcinoma has been reported (Tal et al.,
1988), but it is unclear if this is a frequent event as it has not
been detected by other workers (Yokota et al., 1986).
The physiological action of the c-erbB-2 receptor protein is
unknown and its distribution in human fetal and normal
tissue has yet to be fully characterised. c-erbB-2 mRNA was
widely expressed in organ digests from a single human fetus
(Coussens et al., 1985) but its site within these tissues has
not been identified. Expression of the neu oncogene, the rat
equivalent of c-erbB-2, with which it has 88% homology, has
been described in fetal rats (Kokai et al., 1987) using
Northern blotting and immunocytochemistry. Widespread
staining was demonstrated suggesting an important role for
this protein in fetal development. Such studies are essential,
as knowledge of the normal human fetal tissue distribution
may shed light on the function of this protein, identify
tissues at risk of neoplasia from mutation or amplification of
the gene and delineate organs susceptible to future anti-
oncoprotein (Drebin et al., 1985, 1986; Bernards et al., 1987)
or anti-oncogene therapy.
We have investigated the presence and distribution of the
c-erbB-2 protein by immunocytochemistry and Western blot-
ting in a series of human fetuses and placentae using two
previously described polyclonal antibodies (Gullick et al.,
1987).
Materials and methods
Fifteen whole human fetuses from spontaneous abortions
were collected over several years and stored in 10%
formalin. After processing and embedding four were dis-
carded owing to the presence of mild to severe autolysis,
leaving 11 well preserved fetuses for study. Estimated gestat-
ional ages were determined by a combination of foot length,
crown rump length and histological assessment of tissue
maturity and ranged from 6 to 12 weeks. Fetuses larger than
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12 weeks could not be sectioned whole and were therefore
not included in this study. Tissue from first trimester, second
trimester and term placentae was also studied.
Immunocytochemistry
The rabbit polyclonal antibodies used were previously desig-
nated 20N and 21N (Gullick et al., 1987). These were raised
against synthetic peptides (20N, residues 1215-1225; 21N,
residues 1243-1255) and found to precipitate a 190,000
molecular weight protein with tyrosine kinase activity.
Neither antibody cross-reacted with the EGF receptor.
Fetuses were either routinely processed or when too large
were processed by hand using an extended schedule but the
same reagents. Sections were cut at 4 pm, dewaxed in xylene
and washed in absolute alcohol. Slides were blocked in
methanol peroxide for 20 min, trypsinised (0.1%) at 37°C for
20 min and then incubated in normal swine serum diluted
1:5 for 15 min. Antibody was applied overnight (1:25,
approximately 20ygml-1) and the second layer of biotinyl-
ated swine anti-rabbit antibody (Dako) applied (1:500) for
1 h. The sections were incubated with streptavidin conju-
gated to horseradish peroxidase for 30 min and visualised
after 30 min of amino ethyl carbazole (Zymed) development.
A haematoxylin counter-stain was then applied.
Western blotting
This was performed as previously described (Gullick et al.,
1986) on tissued extracts from a single human fetus (esti-
mated gestational age 12 weeks). Placental vesicles were
prepared from human term placenta (Smith et al., 1977).
Resalts
The pattern of staining of both antibodies was identical,
except for the strong staining of developing and mature red
cells by 21N. 20N gave weaker staining at equivalent
dilutions of antibody. In order to gauge the lability of the c-
erbB-2 protein, two mildly autolytic fetuses were stained.
Patterns of staining similar to those obtained in well pre-
served fetuses were seen, e.g. brain and liver positive,
suggesting that lability was not a problem with this antigen.
Staining patterns have been summarised below and expressed
briefly in tabular form in Table I. Examples of fetuses
stained by 21N and 20N are shown in Figure 1. Individual
fetuses from the four time periods of 6, 8, 10 and 12 weeks
are shown in Figure 2.
Nervous system
Consistent staining of both the central and peripheral
nervous systems was seen at all ages. Staining was strongest
within neural processes and was seen in the ependymal and
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Table I Companrson of tissue distribution of c-erbB-2 receptor and
EGF receptor by immunocytochemistry
c-erbB-2 receptor' EGF receptorb
Central and peripheral
nervous system Diffuse nfsC
Meninges + ns.
Notochord + ns.
Vertebral column + ns.
Developing cartilege Variably positive ns.
Developing bone + ns.
Muscle + n-s.
Skin + +
Dermal mesenchyme Variably positive
Heart + +
Lungs + +
Intestine
Epithelium + +
Submucosa
Muscle Variably positive
Submandibular gland Epithelium + ns.
aThis study (human); bOliver (1988) (human); cNot stated to be
positive.
marginal layers rather than the mantle layer of the develop-
ing brain (Figure 3b) and spinal cord. Staining of neural cell
bodies was seen within the brain and spinal ganglia, but this
varied with gestational age.
All peripheral nerves and the optic nerve were diffusely
positive. The developing eye showed neural staining equi-
valent to the layers of the brain from which it developed.
The cells lining the choroid plexus were always positive.
Musculoskeletal system
The pattern of expression varied with time. Staining was
present in the mesenchyme of the sclerotome of the early
vertebral column at 6 weeks during cartilage formation.
Subsequently immature chondrocytes failed to stain except
for a thin ring of mesenchyme at the periphery of the
vertebral body. With the onset of endochondral ossification
the mature chondrocytes developed strong cytoplasmic stain-
ing which they retained during this process, this was also
present in the osteocytes. In the appendicular skeleton, where
thick bands of mesenchyme surrounded cartilage of greater
maturity, cytoplasmic staining of these cells was seen at an
earlier stage than in the vertebral column. With intramem-
branous ossification within the skull osteoblasts and osteo-
cytes stained strongly.
Rhabdomyoblasts and striated muscle cells were positive
from 6 weeks to 12 weeks, although with increasing maturity
the immunoreactivity of the deeper muscle layers appeared
to decrease.
Cardiorespiratory system
Cardiac muscle was strongly positive throughout; major
arteries, like smooth muscle elsewhere revealed a variable
staining pattern and would be frequently negative. The
respiratory epithelium was consistently positive and during
the period of development of the bronchi staining of the
epithelium and of a cuff of mesenchyme/smooth muscle was
seen (Figure 3c and d). This was maximal towards the
periphery of the lung from 8 to 10 weeks. At 12 weeks only
the bronchial epithelium was staining.
Gastrointestinal system
The epithelial lining of the gut stained whenever it was
present in the sections; oesophageal, gastric, small intestinal
and colonic epithelium stained diffusely but with luminal
accentuation. Staining of the developing smooth muscle wall
of the gut was seen but appeared transient with loss of
staining with maturity. The liver was strongly positive,
membranous staining occurring at 6 weeks and then becom-
ing diffuse. Developing salivary gland acinar epithelium was
positive.
Genitow*uay system
The developing mesonephric glomeruli, tubules and duct all
stained positively with the tubules developing the strong
punctate staining seen in adult proximal tubules (unpub-
lished observations). The developing metanephric glomeruli
and tubules also became positive as did the epithelium of the
metanephric pelvis. The developing gonadal blastema
stained, as did the precursors to the seminiferous tubules.
The adrenal gland was positive with preferential staining of
the central area. The developing pancreatic acini stained
positively.
Skin
The epidermis retained its diffuse positivity as the squamous
epithelium increased in thickness (Figure 3a). The underlying
mesenchyme revealed a variable distribution of staining both
with time and site from negative to intensely positive. The
intensity was always greatest nearest to the basement
membrane.
Placenta
Intense staining ofcyto- and syncytiotrophoblast was seen for
all trimesters.
Western blotting
In order to confirm the pattern of c-erbB-2 expression
observed by immunohistological staining, we prepared
extracts from a variety of normal human fetal tissues and
performed Western blotting using the 21N antibody.
Extracts prepared from the human breast cancer cell line
SKBR-3, which has a 4-8-fold amplification of the c-erbB-2
gene, gave a single band of 190,000mol.wt (Figure 4, tracks
1-3).
Despite several attempts using extracts from fetal tissues
we only obtained a band of the appropriate molecular
weight in extracts prepared from concentrated human
placental vesicles (Figure 4, tracks 4-6). Concentration of
membrane glycoproteins, including the c-erbB-2 protein,
using wheat germ agglutinin sepharose or immuno-
precipitation, did not increase the sensitivity of detection
sufficiently to allow identification of the c-erbB-2 protein in
extracts of other tissue.
The pattern of staining of the c-erbB-2 protein has been
investigated in whole mount fetus preparations during the
first trimester of pregnancy, a period of rapid organogenesis
of nearly all the major adult organ systems. Spontaneous
abortion material was selected which showed no morpho-
logical abnormality and no evidence of autolysis. Of the two
antibodies, 21N gave stronger staining than 20N at the same
dilutions. Both antibodies, however, gave identical staining
patterns with the exception of red blood cells where the
strong positivity for the 21N antibody but not 20N suggests
that this may be a non-specific cross-reaction. This pattern
of reactivity was also seen with non-nucleated adult red
blood cells (unpublished observations).
Expression of the c-erbB-2 oncoprotein was found exten-
sively within all three germ layers in the developing human
fetus suggesting an important role in embryogenesis. Expres-
sion remained relatively constant in tissues derived from66 P. QUIRKE et al.
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Fugwe 1 Eight week human fetus stained with 21N antibody (a) and 10 week human fetus stained with 20N antibody (c) to
c-erbB-2 with their corresponding neptive control of antibody blocked by preincubation with its antigenic peptide (b and d). The
bar indicates 5 mm.
epidermal, endodermal, mesodermal and extraembryonic on-
gins, e.g. muscle, neural tissue and trophoblast; but during
the development of the fetal skeleton it varied over time. The
close co-expression of c-erbB-2 in developing epithelium and
its surrounding mesenchyme, as seen in the lung, skin and
gut, suggests that the c-erbB-2 receptor and its putative
ligand may play a role in mesenchymal-epithelial
communications.
The pattern of expression in the human is remarkably
similar to a study of neu in the fetal rat (Kokai et al., 1987)
and confirms the mRNA work of Coussens et al., (1985) on
a single human fetus. As in the present study, Kokai et al.
(1987), using different antibodies specific for the rat neu
protein, i.e. 7.16.4, 7.9.5 and 7.21.2, detected immunocyto-
chemical staining in the skin, bronchial and gut epithelium,
renal tubules, nervous system, etc.
Western blotting of fresh fetal tissue failed to identify the
c-erbB-2 protein. This approach, however, was successful
when applied to vesicles isolated from extra-embryonic
tissue, the placenta, confirming the immunocytochemical
localisation of this oncoprotein. Comparison of the levels of
expression in Figure 4 suggests that the concentrated
placental preparation contained 30-50 fold less c-erbB-2 pro-
tein per microgram of total protein than do SKBR-3 cells.
Hutman placenta has been reported to contain approximately
5 times as much mRNA for c-erbB-2 than other fetal tissues
(Coussens et al., 1985). These results suggest that in the
absence of specific sensitive radioimmunoassays for the
c-erbB-2 protein, immunocytochemistry remains the best
method of detecting c-erbB-2 protein when expressed at
relatively low levels in normal tissues.
The widespread expression of the c-erbB-2 gene and its
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Fugwe 2 Human fetuses of 6 (a), 8 (b), 10 (c) and 12 (d) weeks gestation demonstrating the pattern of staining with the antibody
21N. The bar indicates 5 mm.
consistent presence in all three embryonic layers places it on
a par with the myc (Zimmerman et al., 1986) and ras (Muller
et al., 1982; Furth et al., 1987) families as a gene with a
general role in fetal development. Other proto-oncogenes,
such as c-ros (Neckameyer et al., 1986), c-src (Cotton &
Brugge, 1983; Sorge et al., 1984; Neckameyer et al., 1986)
and the int family (Jakobovits et al., 1986) appear to have a
much more limited tissue distribution and may be involved
in differentiated functions.
Human fetal epidermal growth factor receptor (EGF-R)
expression has recently been reported by Oliver (1988), who
showed immunocytochemical evidence of limited expression
after 16 weeks of age (see Table I), but none before this,
suggesting that EGF-R has a different role and is less
important in early fetal development than the c-erbB-2
protein. The promoter regions of the EGF receptor (Ishii et
al., 1985) and c-erbB-2 genes (Ishii et al., 1987; Tal et al.,
1987) differ in structure suggesting that different factors
control their rate of transcription.
Growth factor gene expression has been reported for
transforming growth factor-a and P in the fetal mouse.
TGF-x was detected in fetal but not placental extracts from
day 7 to day 13, a period of intense organogenesis
(Twardzik, 1985), epidermal growth factor being absent
during this period. In situ mRNA hybridisation confirmed
the former but also detected TGF-x in placental syncytio-
trophoblast (Wilcox & Derynck, 1988). TGF-f was very
widely expressed in the 11-18 day fetal mouse, as elegantly
demonstrated in an immunocytochemical study by Heine et
al. (1987). They found TGF-# in a range of tissues derived
from mesoderm such as developing cartilage and bone. The
pattern of expression bearing close similarities to that of
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Fugwe 3 Examples of tissue sta g by 21N. a, Developing fetal jaw at 10 weeks with itense saning of osteoblasts and newly
formed osteocytes during osteogenesis, nerve (large arrow), muscle (small arrow) and oral squamous epithelumm b, Fetal brain at 6
weeks with staining of marginal and ependymal layers. c, Fetal lung at 8 weeks with staining of developing bronchial epithelium
and a cuff of mesenchyme. Atrial myocardium can also be seen staining strongly. d, Fetal lung at 10 weeks, mesenchymal staining
present only at the periphery of the lung. Centrally the epithelium still shows immunoreactivity. Magnification of photomicro-
graphs a, b and dx 69; c x44.
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Fugwe 4 Western blot of the c-erbB-2 protein. Tracks 1-3: 1, 2.5
and 5 pg of total protein from the SKBR-3 cell line. Tracks 4-6:
50, 70 and 100 pg of total protein extracted from a preparation
of human placental vesicles.
c-erbB-2 in mesenchymal tissue in the current work. A study
of TGF-fI mRNA by in situ hybridisation confirmed its
presence in fetal tissue, but found a more limited tissue
distribution (Wilcox & Derynck, 1988) of this subclass, and
suggested that the antibodies used by Heine et al. (1987) may
have recognised all the subclasses of TGF-#.
The marked expression of c-erbB-2 reported in this study
in trophoblast is reminiscent of previous work describing
c-myc, c-sis, c-fnms, PDGF receptor and EGF-R activity in
the same population of cells (Muller et al., 1983; Goustin et
al., 1985; Oliver, 1988). The high levels of proto-oncogene
expression possibly relating to the unusual invasive be-
haviour of trophoblast.
The presence of c-erbB-2 abnormalities in salivary, gastric,
renal, pulmonary and colonic adenocarcinoma (see Gullick
& Ventner, 1989; Tal et al., 1988) and in experimental neural
tumours (Lantos et al., 1986; Perantoni et al., 1987) parallels
the pattern of fetal expression. The presence of c-erbB-2
abnormalities in tumours arising from other immunocyto-
chemically positive tissues such as rhabdo-, chondro- and
osteosarcomas or nephro-, neuro- and hepatoblastoma is
unclear but highly likely as Coussens et al. (1985) reported
c-erbB-2 mRNA expression in single examples of four of
these tumour types and Wrba et al. (1989) have recently
demonstrated its presence in cartilagenous tumours. Thus
study of fetal expression of proto-oncogenes may assist in
the selection of tumour types for investigation of oncogene
abnormalities.
We would like to thank Mr S. Toms for photography, Mrs J.
Fearnley for typing the manuscript and Dr AJ. Franks for collec-
ting fetuses from spontaneous abortion material for medical research
over many years.
_ - _c-erbB-2 ONCOPROTEIN IN HUMAN FETUSES 69
References
BERNARDS. R_. DESTREE. A., McKENZIE. S. & 3 others (1987).
Effective tumour immunotherapy directed against an oncogene-
encoded product using a vaccinia virus vector. Proc. Nail Acad.
Sci., 84, 6854.
CLINE. MJ. & BATTIFORA. H. (1987). Abnormalities of proto
oncogenes in non-small cell lung cancer. Cancer, 60, 2669.
COTTON. P.C. & BRUGGE, J.S. (1983). Neural tissues express high
levels of the cellular src gene product pp6O . Molec. Cell. Biol..
3, 1157.
COUSSENS, L., YANG-FENG, T.L., LIAO, Y.-C. & 9 others (1985).
Tyrosine kinase receptor with extensive homology to EGF
receptor shares chromosomal location with neu oncogene.
Science, 230, 1132.
DREBIN. J.A., LINK. V.C., STERN. D.F., WEINBERG, R.A. &
GREENE, M.I. (1985). Down-modulation of an oncogene protein
product and reversion of the transformed phenotype by mono-
clonal antibodies. Cell, 41, 695.
DREBIN. J.A., LINK, V.C., WEINBERG, R.A. & GREENE, M.I. (1986).
Inhibition of tumour growth by a monoclonal antibody reactive
with an oncogene-encoded tumour antigen. Proc. Natl Acad. Sci.,
83, 9129.
FURTH, M.E., ALDRICH, T.H. & CORDON-CARDO, C. (1987).
Expression of ras proto-oncogene proteins in normal tissues.
Oncogene, 1, 47.
GOUSTIN, A.S.. BETSHOLTZ, C., PFEIFFER-OHLSSON, S. & 7 others
(1985). Co expression of the sis and myc proto-oncogenes in
developing human placenta suggests autocrine control of tropho-
blast growth. Cell, 41, 301.
GULLICK, WJ.. DOWNWARD, J., FOULKES, J.G. & WATERFIELD,
M.D. (1986). Antibodies to the ATP-binding site of the human
epidermal growth factor (EGF) receptor as specific inhibitors of
EGF-stimulated protein-tyrosine kinase activity. Eur. J. Bio-
chem., 158, 245.
GULLICK, WJ., BERGER. M.S, BENNETT, P.L.P., ROTHBARD. J.B. &
WATERFIELD, M.D. (1987). Expression of the c-erbB-2 protein in
normal and transformed cells. Int. J. Cancer, 40, 246.
GULLICK, WJ. & VENTER, DJ. (1989). The c-erbB-2 gene and its
expression in human cancers. In The Molecular Biology of
Cancer, Sikora, K. & Waxman J. (eds) p. 38. Blackwell: Oxford.
HEINE, U.L, MUNOZ, E.F., FLANDERS, K.C. & 5 others (1987). Role
of Transforming Growth Factor-f in the development of the
mouse embryo. J. Cell Biol., 105, 2861.
ISHIH, S., XU. Y.-H., STRATTON, R-H. & 3 others (1985). Characteri-
sation and sequence of the promoter region of the human
epidermal growth factor receptor. Proc. Nail Acad. Sci., 82,
4920.
ISHH. S.. IMAMOTO, F. YAMANASHI. Y_ TOYOSHIMA. K. &
YAMAMOTO. T. (1987). Characterisation of the promoter region
of the human c-erbB-2 proto-oncogene. Proc. Nail Acad. Sci.,
84, 4374.
JAKOBOVITS, A.. SHACKLEFORD, G.M., VARMUS, H.E. & MARTIN,
G.R. (1986). Two proto-oncogenes implicated in mammary
carcinogenesis, int-I and int-2, are independently regulated
during mouse development. Proc. Natil Acad. Sci., 83, 7806.
KOKAI, Y., COHEN, J.A., DREBIN, JA. & GREENE, M.I. (1987). Stage
and tissue-specific expression of the neu oncogene in rat develop-
ment. Proc. Natl Acad. Sci.. 84, 8498.
LANTOS, P.L. (1986). Development of nitrosourea-induced brain
tumours - with a special note on changes occurring during
latency. Fed. Chem. Tox., 24, 121.
MULLER, R.. SLAMON, DJ., TREMBLAY, J.M., CLYNE, MJ. &
VERMA, I.M. (1982). Differential expression of cellular oncogenes
during pre- and postnatal development of the mouse. Nature,
299, 640.
MULLER, R. TREMBLAY. J.M., ADAMSON, E.D. & VERMA, I.M.
(1983). Tissue and cell type-specific expression of two human c-
onc genes. Nature, 304, 454.
NECKAMEYER, W.S., SHIBUYA, M.. HSU. M.-T. & WANG, L.-H.
(1986). Proto-oncogene c-ros codes for a molecule with structural
features common to those of growth factor receptors and
displays tissue specific and developmentally regulated expression.
Mfolec. Cell. Biol., 6, 1478.
OLIVER. A.M. (1988). Epidermal growth factor receptor expression
in human foetal tissues is age-dependent. Br. J. Cancer, 58, 461.
PERANTONI, A-O., RICE, J.M., REED, C.D., WATATANI, M. & WENK,
M.L. (1987). Activated neu oncogene sequences in primary
tumours of the peripheral nervous system induced in rats by
transplacental exposure to ethyl nitrosourea. Proc. Nail Acad.
Sci., 84, 6317.
SEMBA. K., KAMATA. N. TOYOSHIMA. K_ & YAMAMOTO. T.
(1985). A v-erbB-related proto-oncogene, c-erbB-2, is distinct
from the c-erbB-1/epidermal growth factor-receptor gene and is
amplified in a human salivary gland adenocarcinoma. Proc. Nail
Acad. Sci., 82, 6497.
SLAMON, DJ., CLARK, G.M.. WONG. S.G.. LEVIN. WJ.. ULLRICH,
A. & McGUIRE, W.L (1987). Human breast cancer correlation of
relapse and survival with amplification of the HER-2/neu onco-
gene. Science, 235, 177.
SMITH, C.H., NELSON, D.M., KING, B.F. & 3 others (1977). Charac-
terization of a microvillous membrane preparation from placen-
tal syncytiotrophoblasts: a morphological, biochemical and
physiological study. Am. J. Obstet. Gmnecol., 128, 190.
SORGE. L.K., LEVY. B.T. & MANESS, P.F. (1984). pp60c-c is develop-
mentally regulated in the neural retina. Cell, 36, 249.
TAL, M., KING, C.R.. KRAUS, M.H., ULLRICH, A. & 3 others (1987).
Human HER2 (neu) promoter evidence for multiple mechanisms
for transcriptional initiation. Molec. Cell. Biol., 7, 2597.
TAL M., WETZLER, Z_, JOSEFBERG. A. & 7 others (1988). Sporadic
amplification of the HER2/neu proto-oncogene in adeno-
carcinomas of various tissues. Cancer Res., 48, 1517.
TWARDZIK, D.R. (1985). Differential expression of transforming
growth factor-2 during prenatal development of the mouse.
Cancer Res., 45, 5413.
VAN DE VIJVER, M., vA DE BERSSELAAR, R., DEVILEE, P. & 3
others (1987). Amplification of the neu (c-erbB-2) oncogene in
human mammary tumours is relatively frequent and is often
accompanied by amplification of the linked c-erbA oncogene.
Molec. Cell. Biol., 7, 2019.
VAN DE VLIVER, MJ., MOOI, WJ., WISMAN, P., PETERSE. J.L. &
NUSSE, R. (1988). Immunohistochemical detection of the neu
protein in tissue sections of human breast tumours with am-
plified neu DNA. Oncogene, 2, 175.
VENTER, DJ., TUZI, N.L., KUMAR. S. & GULLICK, WJ. (1987).
Overexpression of the c-erbB-2 oncoprotein in human breast
carcinomas - immunohistological assessment correlates with gene
amplification. Lancet, ii, 69.
WILCOX, J.N. & DERYNCK. R. (1988). Development expression of
transforming growth factors alpha and beta in mouse fetus.
Molec. Cell. Biol., 8, 3415.
WRBA, F., GULLICK. WJ., FERTL, H., AMANN, G. & SALZER-
KUNTSCHIK, M. (1989). Immunohistochemical detection of the
c-erbB-2 proto-oncogene product in normal, benign and malig-
nant neoplastic human cartilage tissues. Histopathology (in the
press).
YOTOTA, J., YAMAMOTO, T., TOYOSHIMA, K. & 4 others (1986).
Amplification of c-erbB-2 oncogene in human adenocarcinomas
in vivo. Lancet, i 765.
YOKOTA. J., YAMAMOTO, T. MIYAJIMA. N. & 6 others (1988).
Genetic alterations of the c-erbB-2 oncogene occur frequently in
tubular adenocarcinoma of the stomach and are often accom-
panied by amplifcation of the v-erb-A homologue. Oncogene, 2,
283.
ZHOU, D., BATIIIFORA, H., YOKOTA, J.. YAMAMOTO. T. & CLINE,
MJ. (1987). Association of multiple copies of the c-erbB-2
oncogene with spread of breast cancer. Caner Res., 47, 6123.
ZIMMERMAN, KA., YANCOPOLTLOS. G.D.. COLLUM, R.G. & 9
others (1986). Differential expression of myc family genes during
murine development. Nature, 319, 780.